GSE110186

NOD2- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn’s disease patients

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Employing microarray assays, a total of 267 genes were identified that were significantly up- or downregulated in PBMCs of WT-NOD2 patients, compared to healthy donors after challenge with vitamin D (+/-D) and/or a combination (+/-LP) of LPS (lipopolysaccharide) and PGN (peptidoglycan) (p < 0.05; threshold: ≥ 2-fold change). For further analysis by real-time PCR, 12 genes with known impact on inflammation and immunity were selected that fulfilled predefined expression criteria. In a larger cohort of patients and controls, a disease-associated expression pattern, with higher transcript levels in vitamin D-treated PBMCs from 5 patients, was observed for three of these genes, CLEC5A (p < 0.030), lysozyme (LYZ; p < 0.047) and TREM1 (p < 0.023). Six genes were found to be expressed in a NOD2- dependent manner (CD101, p < 0.002; CLEC5A, p < 0.020; CXCL5, p < 0.009; IL-24, p < 0.044; ITGB2, p < 0.041; LYZ, p < 0.042). Interestingly, the highest transcript levels were observed in patients with heterozygous NOD2 mutations.

Overall design

PBMC`s of 3 patient and 3 controls were treated with vitamin D and/or a combination of LPS and PGN resulting in 8 triplicates (24 hybridization samples)

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
24 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

1 linked publication 1 DOI

Primary publication

  1. NOD2- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn's disease patients. World journal of gastroenterology, 2018
Available

Metadata Quality Components

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Crohn's disease Disease context came from Normalization rules.
  • Likely case group Treated 18 samples
  • Likely control group Healthy control 6 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a biofluid cohort. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Treatment vs control. Specimen: Biofluid. Comparison suitability: 0%.
  • Interpreted disease metadata: Crohn's disease.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 1 publication; 1 DOI available: PMID 29568200.
  • Publication context: NOD2- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn's disease patients.. World journal of gastroenterology, 2018. PMID 29568200. DOI 10.3748/wjg.v24.i11.1196.

Cautions

  • Downgraded for tissue search because it is a biofluid cohort.
  • Downgraded for tissue search because it is a treatment/control experiment.
  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Treatment/control experiment downgraded because this ranking targets tumor-vs-normal tissue comparisons.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Microarray expression context downgraded below primary bulk RNA-seq for the default tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because microarray cohorts should be compared separately from RNA-seq cohorts.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

172 fields

Sample Group Preview

24 rows shown
Show Hide
Study totals: Case 18 | Control 6 | Unassigned 0 | Excluded 0 | Ambiguous 0 24 rows shown
Group Role Accession Title Source / characteristics Reason
Treated Case GSM2981862 Control_1_+D+LP, biological replicate 1 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: Vitamin D/lipopolysaccharide/peptidoglycan Treatment case marker detected.
Treated Case GSM2981863 Control_2_+D+LP, biological replicate 2 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: Vitamin D/lipopolysaccharide/peptidoglycan Treatment case marker detected.
Treated Case GSM2981864 Control_3_+D+LP, biological replicate 3 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: Vitamin D/lipopolysaccharide/peptidoglycan Treatment case marker detected.
Treated Case GSM2981868 Control_1_-D+LP, biological replicate 1 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: Lipopolysaccharide and peptidoglycan Treatment case marker detected.
Treated Case GSM2981869 Control_2_-D+LP, biological replicate 2 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: Lipopolysaccharide and peptidoglycan Treatment case marker detected.
Treated Case GSM2981870 Control_3_-D+LP, biological replicate 3 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: Lipopolysaccharide and peptidoglycan Treatment case marker detected.
Treated Case GSM2981874 Patient_1_+D+LP, biological replicate 1 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: Vitamin D/lipopolysaccharide/peptidoglycan Treatment case marker detected.
Treated Case GSM2981875 Patient_2_+D+LP, biological replicate 2 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: Vitamin D/lipopolysaccharide/peptidoglycan Treatment case marker detected.
Treated Case GSM2981876 Patient_3_+D+LP, biological replicate 3 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: Vitamin D/lipopolysaccharide/peptidoglycan Treatment case marker detected.
Crohn's disease Case GSM2981877 Patient_1_+D-LP, biological replicate 1 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: Vitamin D Case marker detected.
Crohn's disease Case GSM2981878 Patient_2_+D-LP, biological replicate 2 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: Vitamin D Case marker detected.
Crohn's disease Case GSM2981879 Patient_3_+D-LP, biological replicate 3 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: Vitamin D Case marker detected.
Treated Case GSM2981880 Patient_1_-D+LP, biological replicate 1 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: Lipopolysaccharide and peptidoglycan Treatment case marker detected.
Treated Case GSM2981881 Patient_2_-D+LP, biological replicate 2 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: Lipopolysaccharide and peptidoglycan Treatment case marker detected.
Treated Case GSM2981882 Patient_3_-D+LP, biological replicate 3 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: Lipopolysaccharide and peptidoglycan Treatment case marker detected.
Crohn's disease Case GSM2981883 Patient_1_-D-LP, biological replicate 1 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: None Case marker detected.
Crohn's disease Case GSM2981884 Patient_2_-D-LP, biological replicate 2 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: None Case marker detected.
Crohn's disease Case GSM2981885 Patient_3_-D-LP, biological replicate 3 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Crohn’s disease; Treatment: None Case marker detected.
Healthy control Control GSM2981865 Control_1_+D-LP, biological replicate 1 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: Vitamin D Sample-local control marker detected.
Healthy control Control GSM2981866 Control_2_+D-LP, biological replicate 2 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: Vitamin D Sample-local control marker detected.
Healthy control Control GSM2981867 Control_3_+D-LP, biological replicate 3 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: Vitamin D Sample-local control marker detected.
Healthy control Control GSM2981871 Control_1_-D-LP, biological replicate 1 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: None Sample-local control marker detected.
Healthy control Control GSM2981872 Control_2_-D-LP, biological replicate 2 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: None Sample-local control marker detected.
Healthy control Control GSM2981873 Control_3_-D-LP, biological replicate 3 PBMCs by density-gradient centrifugation Tissue: PBMC; Disease state: Healthy donor; Treatment: None Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.